[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100441626":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":59,"collaborators":26,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":26,"enrollmentInfo":71,"targetDuration":26,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":45,"whyStopped":26,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Fundación EPIC","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Polypill","EXPERIMENTAL","Patients will be receiving the polypill at the adequate doses during 3 months",[13],"Drug: Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin",{"label":15,"type":16,"description":17,"interventionNames":18},"Drugs taken separately","ACTIVE_COMPARATOR","Patients will be receiving during 3 months the same components and at the same doses than with the polypill",[19],"Drug: Polypill of acetylsalicylic acid, ramipril and atorvastatin",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Polypill of acetylsalicylic acid, ramipril and atorvastatin","Administration of acetylsalicylic acid, ramipril and atorvastatin in a polypill during 3 months more",[15],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Drugs taken separately: acetylsalicylic acid, ramipril and atorvastatin","Patients will be receiving during 3 months more the same components acetylsalicylic acid, ramipril and atorvastatin than with the polypill",[9],[32],{"name":33,"affiliation":34,"role":35},"Iñigo Lozano, MD, PHD","Hospital de Cabueñes, Gijon","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Iñigo Lozano Martinez-Luengas, MD, PHD","CONTACT","+34630901145","inigo.lozano@gmail.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Hospital Universitario de Cabueñes","RECRUITING","Gijón","Principality of Asturias","33203","Spain","ES",{"type":52,"coordinates":53},"Point",[54,55],-5.66152,43.53573,{"lat":55,"lon":54},[58],{"name":33,"role":39,"phone":40,"phoneExt":26,"email":41},{"type":60,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100441626","phase-4-cross-over-study-of-coronary-risk-factors-with-a-polypill-100441626",false,"NCT05030818","Cross-over Study of Coronary Risk Factors With a Polypill","Cross-over Analysis of the Control of Coronary Risk Factors and Level of Platelet Inhibition With a Polypill","POLICROSS","Inclusion Criteria:\n\nPatients over 18 years of age. Patients under treatment with the Trinomia® polypill in any of its presentations for indication of secondary prevention and who can make the 6 visits necessary to complete the study. Patients who sign the Informed Consent.\n\nExclusion Criteria:\n\nPatients who do not sign the informed consent. Patients with an inability to understand and comply with the protocol. Patients with contraindication to any component of the polypill. Patients who are already participating in another clinical trial. Patients with any condition that limits life expectancy to \\\u003C1 year. Patients with programmed coronary revascularization. Patients with coronary stent implantation in the last 12 months. Patients treated with any antithrombotic drug in addition to acetylsalicylic acid, that is, low molecular weight heparin, P2Y12 receptor inhibitors, or oral anticoagulants.","ALL","18 Years",{"count":72,"type":73},88,"ESTIMATED","INTERVENTIONAL",[76],"PHASE4","Open-label, randomized, cross-over study conducted in a single center, applied to patients receiving a polypill with 100 mg of acetyl salicylic acid and different doses of ramipril and atorvastatin for indication of secondary prevention according to clinical practice, with objective of analyzing the level of systolic blood pressure and LDL-cholesterol in the same patient in 2 different periods: one under treatment of 3 months with the polypill and another of 3 months with the components separately.",[79],"Coronary Artery Disease",[81,82,83],"Hypertension","LDL-cholesterol","Platelet inhibition","2025-08-04",{"date":86,"type":87},"2025-08-05","ACTUAL",{"date":89,"type":87},"2022-10-14",{"date":91,"type":73},"2026-04-30",{"name":5,"class":6},1]